Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34+CD38- cells expressing Flk2/Flt3 - PubMed (original) (raw)
Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34+CD38- cells expressing Flk2/Flt3
Yasuhiro Ebihara et al. Br J Haematol. 2002 Nov.
Free article
Abstract
In the present study, we examined the expression of Flk2/Flt3, a tyrosine kinase receptor, on human cord blood CD34+ haematopoietic progenitor/stem cells. In flow cytometric analysis, Flk2/Flt3 was expressed on 80% of CD34+ cells and their immature subpopulations, CD34+CD33- and CD34+CD38- cells. Methycellulose clonal culture of sorted CD34+Flk2/Flt3+ and CD34+Flk2/Flt3- cells showed that most of myelocytic progenitors expressed Flk2/Flt3, but erythroid and haematopoietic multipotential progenitors were shared by both fractions. When 1 x 10(4) lineage marker-negative (Lin-)CD34+Flk2/Flt3- cells were transplanted into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, none of the recipients possessed human CD45+ cells in bone marrow 11-12 weeks after the transplantation. In contrast, all recipients transplanted with 1 x 10(4) Lin-CD34+Flk2/Flt3+ cells showed successful engraftment. Furthermore, clonal cells expanded from single Lin-CD34+CD38-Flk2/Flt3+ cells in the culture with Flk2/Flt3 ligand, stem cell factor, thrombopoietin, and a complex of interleukin 6/soluble interleukin 6 receptor were individually transplanted into NOD/SCID mice. At 20 to 21 weeks after the transplantation, three out of 10 clones harvested at d 7 of culture, and three out of six clones at d 14 could reconstitute human haematopoiesis in recipient marrow. These results demonstrated that Flk2/Flt3 was expressed on a wide variety of human haematopoietic cells including long-term-repopulating haematopoietic stem cells.
Similar articles
- Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor.
Ueda T, Tsuji K, Yoshino H, Ebihara Y, Yagasaki H, Hisakawa H, Mitsui T, Manabe A, Tanaka R, Kobayashi K, Ito M, Yasukawa K, Nakahata T. Ueda T, et al. J Clin Invest. 2000 Apr;105(7):1013-21. doi: 10.1172/JCI8583. J Clin Invest. 2000. PMID: 10749580 Free PMC article. - Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells.
Guenechea G, Segovia JC, Albella B, Lamana M, Ramírez M, Regidor C, Fernández MN, Bueren JA. Guenechea G, et al. Blood. 1999 Feb 1;93(3):1097-105. Blood. 1999. PMID: 9920860 - Reversible cell surface expression of CD38 on CD34-positive human hematopoietic repopulating cells.
McKenzie JL, Gan OI, Doedens M, Dick JE. McKenzie JL, et al. Exp Hematol. 2007 Sep;35(9):1429-36. doi: 10.1016/j.exphem.2007.05.017. Epub 2007 Jul 25. Exp Hematol. 2007. PMID: 17656009 - Ex vivo expansion of human hematopoietic stem cells.
Nakahata T. Nakahata T. Int J Hematol. 2001 Jan;73(1):6-13. doi: 10.1007/BF02981897. Int J Hematol. 2001. PMID: 11372756 Review. - Purification and functional assay of pluripotent hematopoietic stem cells.
Peschle C, Botta R, Müller R, Valtieri M, Ziegler BL. Peschle C, et al. Rev Clin Exp Hematol. 2001 Mar;5(1):3-14. doi: 10.1046/j.1468-0734.2001.00029.x. Rev Clin Exp Hematol. 2001. PMID: 11486731 Review.
Cited by
- High expression of FLT3 is a risk factor in leukemia.
Cheng J, Qu L, Wang J, Cheng L, Wang Y. Cheng J, et al. Mol Med Rep. 2018 Feb;17(2):2885-2892. doi: 10.3892/mmr.2017.8232. Epub 2017 Dec 8. Mol Med Rep. 2018. PMID: 29257272 Free PMC article. - Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA. Voutsadakis IA. Med Oncol. 2003;20(4):311-24. doi: 10.1385/MO:20:4:311. Med Oncol. 2003. PMID: 14716027 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous